Features of therapy of resistant forms of chlamydial infection
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: the analysis of the effectiveness of treatment of resistant forms of urogenital chlamydia in using a combination of antibiotic therapy with an inducer of endogenous interferon Overseen.
Materials and methods. 38 men with urogenital chlamydiosis, in combination with chronic prostatitis, were examined. Patients were divided into groups. The main group included 20 patients, in the comparison group – 18 patients, in the control group – 20 practically healthy men. All patients before and after treatment were monitored for clinical, biochemical, immunological parameters of blood. The main group (20 patients) received antibacterial therapy in combination with Overin (250 mg IM once a day, every other day, only 10 injections). Patients in the comparator group received standard doxycycline therapy of 200–400 mg per day for 14 days.
Results. After the treatment of urogenital chlamydia, the immune parameters of the blood improved to a greater extent in patients receiving an endogenous interferon inducer. Control of cure of patients who participated in the study was performed 30 and 60 days after the completion of etiotropic therapy. In patients of the main group who additionally received Overin, elimination of the pathogen was achieved in 95% of cases, in the comparison group this indicator was 88.8%. 30 days after the treatment, only 2 (10%) patients in the main group maintained dysuric syndrome, while in the group comparing the increase in urination was noted in 6 (33.3%) patients. Chronic pain in the pelvic organs after treatment was maintained in 1 (5%) of the patients in the primary group and in 3 (16.6%) patients in the comparison group.
Conclusion. The use of Overin in combination with antibacterial agents increases the effectiveness of the treatment of resistant forms of urogenital chlamydia and accelerates the regression of dysuric phenomena and pain in pelvic organs associated with chronic prostatitis. Overin is well tolerated by patients and does not have clinically significant side effects.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Мавров Г.И. Урогенитальный микоплазмоз: непростой выбор антибактериальной терапии (обзор литературы и собственные исследования) / Г.И. Мавров, Т.В. Федорович // Укр. журн. дерматол., венерол., косметол. – 2016. – № 1 (60). – С. 74–79.
Мавров Г.И. Хламидийные инфекции: биология возбудителей, патогенез, клиника, диагностика, лечение, профилактика / Г.И. Мавров. – К.: Геркон, 2005. – 524 с.
Мавров Г.И. Особенности микрофлоры урогенитального тракта при воспалительных заболеваниях мочеполовых органов / Г.И. Мавров, Г.П. Чинов, И.Н. Никитенко // Укр. журн. дерматол., венерол., косметол. – 2004. – № 2 (13). – С. 64–68.
Соколовский Е.В., Глазыкова Л.К., Герасимова Н.М. Урогенитальная хламидийная инфекция. Под ред. Соколовского Е.В. – С-П: Сотис, 1998.
Щербакова Ю.В. Чутливість збудників захворювань урогенітального тракту до антибактеріальних препаратів та склад біотопу у пацієнтів з інфекціями, що передаються статевим шляхом / Ю.В. Щербакова, Г.И. Мавров, С.К. Джораєва, В.В. Гончаренко // Дерматологія та венерологія. – 2016. – № 1 (71). – С. 49–56.
Interstitial cystitis and infectious agents [Text] / D. Fioriti, M. Penta, M. Mischitelli, A.M. Degener, et al. // Int.J. Immunopathol. Pharmacol. – 2005. – Vol. 18, № 4. – P. 799–804. https://doi.org/10.1177/039463200501800424
Land J.A., Van Bergen J.E.A.M., Morre S.A., Postma M.J. Epidemiology of Chlamydia trachomatis infection in women and the cost effectiveness ofscreening. Human Reproduction Update 2010; 16 (2): 189–204. https://doi.org/10.1093/humupd/dmp035
Van Bergen JEAM, De Feijter E.M., Gotz H.M., CSI Netherlands 2007–2010: A Large Scale Internet Based Chlamydia Screening Implementation Programme.Seattle, USA: Abstract book 17th ISSTDR, 2007.
Oakeshott P., Kerry S., Aghaizu A. et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease:the POPI (prevention of pelvic infection) trial. BMJ 2010; 340: 16–42. https://doi.org/10.1136/bmj.c1642
Serov V.N., Sukhikh G.T. Rational pharmacotherapy in obstetrics, gynecology and neonatology. – M: Litterra 2010. Рациональная фармакотерапия в акушерстве, гинекологии и неонатологии. Под ред. В.Н. Серова, Г.Т. Сухих. – М.: Литтерра, 2010.
Gupta R.S. The phylogeny of proteobacteria: relationships to other eubacteriol phyla and eukaryotes // FEMS Microbiol. Rev. – 2000. – Vol. 24, № 4. – P. 367–402. https://doi.org/10.1111/j.1574-6976.2000.tb00547.x
